Vaccines Market Size & Share, by Type (Inactivated, Recombinant, Live Attenuated, Toxoid); Administration Route (Oral, Parenteral); Age Group (Adults, Pediatric); Application {Viral Diseases (Influenza, Hepatitis, Herpes Zoster, Rubella, Rotavirus), Bacterial Diseases (Diphtheria, Meningococcal, Pneumococcal)}; Distribution Channel (Government Supplier, Hospitals) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 1399
  • Published Date: Feb 06, 2023
  • Report Format: PDF, PPT

Companies Dominating the Vaccines Landscape

top-features-companies
    • GlaxoSmithKline plc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Pfizer Inc.
    • Sanofi Aventis
    • Merck & Co., Inc.
    • Mitsubishi Tanabe Pharma Corporation
    • Bavarian Nordic A/S
    • Novartis AG
    • Inovio Pharmaceuticals, Inc.
    • CSL Limited
    • Emergence BioSolutions, Inc.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Pfizer Inc. to reveal the positive results from the Phase 3 study that has been recently conducted. The data from the study defines the 20-valent pneumococcal conjugate vaccine candidate. Apart from accomplishing positive results, the vaccine is still on its way to acquiring approval from requisite agencies.
  • GlaxoSmithKline plc to acquire prequalification from the World Health Organization (WHO) Mosquirix, additionally known as RTS, S/AS01. With this accomplishment, Mosquirix becomes the only approved vaccine for malaria. Furthermore, the vaccine I ready to be rolled out in the countries with a higher prevalence of P. falciparum malaria transmission.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 1399
  • Published Date: Feb 06, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing demand for vaccines to cure hepatitis b and increasing cases of tuberculosis across the globe are estimated to majorly boost the market growth.

The market is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2023-2033.

The requirement for higher initial investment and long-lasting and costly procedure of R&D of the vaccine is estimated to challenge the market growth.

The market in the Asia Pacific is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Pfizer Inc., Sanofi Aventis, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Bavarian Nordic A/S, Novartis AG, Inovio Pharmaceuticals, Inc., CSL Limited, and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, administration route, age group, application, distribution channel, and by region.

The bacterial diseases segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying